Cover Image
市場調查報告書

Isis Pharmaceuticals, Inc.:開發中產品分析

Isis Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224579
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
Isis Pharmaceuticals, Inc.:開發中產品分析 Isis Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年04月30日 內容資訊: 英文 78 Pages
簡介

Isis Pharmaceuticals, Inc.是專精於反義核酸技術的生物醫藥品企業。

本報告提供Isis Pharmaceuticals, Inc.所開發治療用平台產品的開發狀況調查分析,提供研究·開發概要,開發中產品的概要,實驗各階段產品概要,藥物簡介,開發平台分析,企業資料等相關資料,為您提供系統性資訊。

目錄

Isis Pharmaceuticals, Inc.概要

Isis Pharmaceuticals, Inc. - 研究·開發概要

  • 主要治療領域

Isis Pharmaceuticals, Inc. - 開發平台檢驗

  • 開發中產品:各開發階段
  • 開發中產品 - 單獨療法
  • 開發中產品 - 聯盟產品
  • 開發中產品 - 轉出授權產品

Isis Pharmaceuticals, Inc. - 開發中產品的概要

  • 開發中產品 - 後期階段的開發中產品
  • 開發中產品 - 臨床實驗階段的開發中產品
  • 開發中產品 - 初期階段的開發中產品

Isis Pharmaceuticals, Inc. - 藥物簡介

  • ISIS-TTRRx
  • ISIS-APOCIIIRx
  • ISIS-CRPRx
  • ISIS-EIF4ERx
  • ISIS-FXIRx
  • ISIS-GCCRRx
  • ISIS-GCGRRx
  • ISIS-PTP1BRx
  • ISIS-SMNRx
  • ISIS-ANGPTL3 Rx
  • ISIS-APOARx
  • ISIS-FGFR4Rx
  • ISIS-HBVRx
  • ISIS-SOD1Rx
  • CideB Antisense Oligonucleotide
  • ISIS-AATRx
  • ISIS-DGAT2Rx
  • ISIS-DMPKRx
  • ISIS-FVIIRx
  • ISIS-GSK4 Rx
  • ISIS-HTTRx
  • ISIS-PKKRx
  • Antisense Oligonucleotides for Neurology

Isis Pharmaceuticals, Inc. - 開發平台分析

  • 開發中產品:標的別
  • 開發中產品:各給藥途徑
  • 開發中產品:各類型分子
  • 開發中產品:各作用機制

Isis Pharmaceuticals, Inc. - 開發中產品的最新趨勢

Isis Pharmaceuticals, Inc. - 暫停的計劃

Isis Pharmaceuticals, Inc. - 中止的開發中產品

Isis Pharmaceuticals, Inc. - 財務報表

Isis Pharmaceuticals, Inc. - 所在地與子公司

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06994CDB

Summary

Global Markets Direct's, 'Isis Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Isis Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Isis Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Isis Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Isis Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Isis Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Isis Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Isis Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Isis Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Isis Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Isis Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Isis Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Isis Pharmaceuticals, Inc. Snapshot
    • Isis Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Isis Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Isis Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Isis Pharmaceuticals, Inc. - Pipeline Products Glance
    • Isis Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Isis Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Isis Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Isis Pharmaceuticals, Inc. - Drug Profiles
    • ISIS-TTRRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nusinersen
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-CRPRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-EIF4ERx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-FXIRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-GCCRRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-GCGRRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-PTP1BRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-DMPK-2.5
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-APOALRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-FGFR4Rx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-HBVRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-PKKRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit C9ORF72 Protein for Amyotrophic Lateral Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-AATRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-AGTLRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-APOCIIILRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-BIIB3Rx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-DGAT2Rx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-FVIIRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-GHRLRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-HTTRx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISISGSK-4L
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISISGSK-6L
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISISRHO-2.5Rx
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide 1 for Neurological and Neuromuscular Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide 2 for Neurological and Neuromuscular Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Isis Pharmaceuticals, Inc. - Pipeline Analysis
    • Isis Pharmaceuticals, Inc. - Pipeline Products by Target
    • Isis Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Isis Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Isis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Isis Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Isis Pharmaceuticals, Inc. - Dormant Projects
  • Isis Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ISIS-104838
      • ISIS-113715
      • ISIS-14803
      • ISIS-2503
      • ISIS-5132
      • ISIS-CRPRx
      • ISIS-EIF4ERx
  • Isis Pharmaceuticals, Inc. - Company Statement
  • Isis Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Isis Pharmaceuticals, Inc., Key Information
  • Isis Pharmaceuticals, Inc., Key Facts
  • Isis Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Isis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Isis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Isis Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Isis Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Isis Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Isis Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Isis Pharmaceuticals, Inc. - Phase III, 2015
  • Isis Pharmaceuticals, Inc. - Phase II, 2015
  • Isis Pharmaceuticals, Inc. - Phase I, 2015
  • Isis Pharmaceuticals, Inc. - Preclinical, 2015
  • Isis Pharmaceuticals, Inc. - Discovery, 2015
  • Isis Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Isis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Isis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Isis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Isis Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Isis Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Isis Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015
  • Isis Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Isis Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Isis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Isis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Isis Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Isis Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Isis Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Isis Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Isis Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Isis Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top